Healthcare provider profile · identity verified

Cara Strobel, DO

Family Practice · PLYMOUTH, MA · NPI 1831752666

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	330	104
Levothyroxine Sodium	Levothyroxine Sodium	224	64
Amlodipine Besylate	Amlodipine Besylate	209	63
Lisinopril	Lisinopril	180	54
Omeprazole	Omeprazole	170	59
Losartan Potassium	Losartan Potassium	144	46
Metoprolol Succinate	Metoprolol Succinate	132	41
Simvastatin	Simvastatin	120	36
Rosuvastatin Calcium	Rosuvastatin Calcium	119	46
Hydrochlorothiazide	Hydrochlorothiazide	110	39
Trazodone Hcl	Trazodone Hcl	104	37
Sertraline Hcl	Sertraline Hcl	81	23
Metformin Hcl	Metformin Hcl	77	27
Gabapentin	Gabapentin	64	24
Lorazepam	Lorazepam	56	19
Furosemide	Furosemide	53	16
Pantoprazole Sodium	Pantoprazole Sodium	53	20
Albuterol Sulfate Hfa	Albuterol Sulfate	52	21
Quetiapine Fumarate	Quetiapine Fumarate	46	suppressed
Famotidine	Famotidine	43	18
Ozempic	Semaglutide	41	suppressed
Alprazolam	Alprazolam	38	suppressed
Citalopram Hbr	Citalopram Hydrobromide	37	11
Metformin Hcl Er	Metformin Hcl	37	13
Escitalopram Oxalate	Escitalopram Oxalate	36	14
Pravastatin Sodium	Pravastatin Sodium	36	11
Fluticasone Propionate	Fluticasone Propionate	34	16
Trulicity	Dulaglutide	34	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	11
Metoprolol Tartrate	Metoprolol Tartrate	33	12
Diazepam	Diazepam	32	suppressed
Potassium Chloride	Potassium Chloride	32	13
Xarelto	Rivaroxaban	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Eliquis	Apixaban	26	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	12
Tamsulosin Hcl	Tamsulosin Hcl	25	suppressed
Valsartan	Valsartan	25	suppressed
Atenolol	Atenolol	24	suppressed
Mounjaro	Tirzepatide	24	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Nystatin	Nystatin	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Baclofen	Baclofen	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Irbesartan	Irbesartan	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	11
Clonazepam	Clonazepam	19	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Azithromycin	Azithromycin	16	16
Buspirone Hcl	Buspirone Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Finasteride	Finasteride	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Mesalamine	Mesalamine	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Fluconazole	Fluconazole	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Glipizide	Glipizide	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error